- STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&AProving out a "synthetic lethality" approach can help treat cancer will take a lot more work. It also might trigger some creative deal-making.STAT · 1mo ago↗ source
- HHS responds coolly to paper on alcohol riskSoda and liver cancer, scientists conflicted on a new NIH proposal, and more health news from Morning RoundsSTAT · 1mo ago↗ source
- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test<figure><div><img src="https://imgproxy.divecdn.com/-VJqYiEfcoBd7qksclMxxfyJncEOUGAsA4I3KzG8Vpc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzM4Mzc0MDE5LmpwZ…BioPharma Dive · 1mo ago↗ source